Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine in HIV-infected adults on combination antiretroviral therapy: a phase I/II, randomized trial

Thacher, Eleonora G.a,*; Cavassini, Matthiasb,*; Audran, Réginea; Thierry, Anne-Christinea; Bollaerts, Annec; Cohen, Joec; Demoitié, Marie-Angec; Ejigu, Dawitc; Mettens, Pascalc; Moris, Philippec; Ofori-Anyinam, Opokuac,†; Spertini, Françoisa,†


In this paper by Eleonora et al. [1], there is an error in the legend of the Y-axis of Fig 4a: M72-specific CD4+ T-cell responses following vaccination with M72/A S01.

The legend of Y-axis in Fig 4a incorrectly refers to ‘M72-specific CD4+ T cells expressing at least 3 markers (%)’. The correct Y-axis legend should read ‘M72-specific CD4+ T cells expressing at least 2 markers (%)’.

Please see the corrected Fig 4a here.

AIDS. 29(7):865, April 24, 2015.

doi: 10.1097/QAD.0000000000000343
Clinical Science

Objective: Tuberculosis (TB) is highly prevalent among HIV-infected people, including those receiving combination antiretroviral therapy (cART), necessitating a well tolerated and efficacious TB vaccine for these populations. We evaluated the safety and immunogenicity of the candidate TB vaccine M72/AS01 in adults with well controlled HIV infection on cART.

Design: A randomized, observer-blind, controlled trial (NCT00707967).

Methods: HIV-infected adults on cART in Switzerland were randomized 3 : 1 : 1 to receive two doses, 1 month apart, of M72/AS01, AS01 or 0.9% physiological saline (N = 22, N = 8 and N = 7, respectively) and were followed up to 6 months postdose 2 (D210). Individuals with CD4+ cell counts below 200 cells/μl were excluded. Adverse events (AEs) including HIV-specific and laboratory safety parameters were recorded. Cell-mediated (ICS) and humoral (ELISA) responses were evaluated before vaccination, 1 month after each dose (D30, D60) and D210.

Results: Thirty-seven individuals [interquartile range (IQR) CD4+ cell counts at screening: 438–872 cells/μl; undetectable HIV-1 viremia] were enrolled; 73% of individuals reported previous BCG vaccination, 97.3% tested negative for the QuantiFERON-TB assay. For M72/AS01 recipients, no vaccine-related serious AEs or cART-regimen adjustments were recorded, and there were no clinically relevant effects on laboratory safety parameters, HIV-1 viral loads or CD4+ cell counts. M72/AS01 was immunogenic, inducing persistent and polyfunctional M72-specific CD4+ T-cell responses [medians 0.70% (IQR 0.37–1.07) at D60] and 0.42% (0.24–0.61) at D210, predominantly CD40L+IL-2+TNF-α+, CD40L+IL-2+ and CD40L+IL-2+TNF-α+IFN-γ+]. All M72/AS01 vaccines were seropositive for anti-M72 IgG after second vaccination until study end.

Conclusion: M72/AS01 was clinically well tolerated and immunogenic in this population, supporting further clinical evaluation in HIV-infected individuals in TB-endemic settings.

aDivision of Immunology and Allergy

bService of Infectious Diseases, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland

cGlaxoSmithKline Vaccines, Rixensart, Belgium.

*The authors Eleonora G. Thacher and Matthias Cavassini contributed equally to the writing of this article.

Opokua Ofori-Anyinam and François Spertini are equal senior authors.

Correspondence to François Spertini, Division of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois (CHUV-BH19), Rue du Bugnon, CH-1011 Lausanne, Switzerland. Tel: +41 21 314 0799; fax: +41 21 314 0801; e-mail:

Received 3 December, 2013

Revised 5 May, 2014

Accepted 6 May, 2014

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Website (

© 2014 Lippincott Williams & Wilkins, Inc.